SES · H02.SI
Haw Par Corporation Limited
SGD 12.96+SGD 0.08 (+0.62%)
Haw Par Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
Loading market information…
SES · 42C.SI · SGD
Stock price, earnings
Quote as of Oct 30, 2026, 09:06 AM UTC. Cached market data; not a live quote.
One-year closing-price history · SGD. Historical prices are not a forecast.
iX Biopharma Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.4% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow iX Biopharma Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical enterprise headquartered in Singapore since its inception in 2004, focuses on the research, development, manufacturing, and commercialization of therapeutic solutions. The company targets acute and breakthrough pain, alongside various other health conditions, serving markets in Singapore, the United States, China, and Australia through its Specialty Pharmaceutical and Nutraceutical divisions. Its commercial offerings include Wafesil and Silcap, both indicated for male erectile dysfunction. Additionally, the company markets Xativa, a sublingual cannabidiol wafer, and Hypera, a sublingual tetrahydrocannabinol wafer, which address chronic pain, anxiety, and insomnia. iX Biopharma boasts an extensive product pipeline. Wafermine, a racemic ketamine sublingual wafer designed for complex regional pain syndrome and psychiatric conditions like depression, has successfully advanced through Phase 2 clinical trials. Other investigational candidates that have completed Phase 1 trials include iXB 120 for acute agitation, IXB-214 for complex regional pain syndrome, and IXB-314 for treatment-resistant depression. Furthermore, BnoX is currently undergoing Phase 1 evaluation for moderate to severe pain. In earlier development stages, iXB 401, a sublingual semaglutide wafer, is in pre-clinical development for Type 2 Diabetes and obesity. The pipeline also encompasses SL-NAD+, a sublingual NAD+ wafer engineered to boost the body's NAD+ levels, energy, and alertness; a distinct NAD+ product targeting sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafer for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer offering benefits for skin brightening and immunity.
Latest available per-share figures in SGD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:01 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SGD 12.96+SGD 0.08 (+0.62%)
Haw Par Corporation Limited’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
SGD 0.82+SGD 0.01 (+0.61%)
Raffles Medical Group Ltd’s quoted price sits in the lower half of its reported 52-week range, 24.07% below the high.
SGD 0.05+SGD 0.00 (+2.13%)
Thomson Medical Group Limited’s quoted price sits in the lower half of its reported 52-week range, 28.36% below the high.
SGD 0.74-SGD 0.01 (-0.68%)
Riverstone Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 25.38% below the high.
$9.58-$0.70 (-6.81%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 44.29% below the high.
$0.46-$0.02 (-3.16%)
UltraGreen.ai Limited’s quoted price sits in the lower half of its reported 52-week range, 75.27% below the high.
SGD 0.49SGD 0.00 (0.0%)
Q & M Dental Group (Singapore) Limited’s quoted price sits in the lower half of its reported 52-week range, 22.83% below the high.
₩4,020-₩135 (-3.25%)
Prestige BioPharma Limited’s quoted price sits in the lower half of its reported 52-week range, 71.53% below the high.
